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The rising incidence rate of the cancer in the prostate gland has increased the demand for
improved diagnostic, imaging, and therapeutic approaches. Prostate-specific membrane
antigen (PSMA), with folate hydrolase and carboxypeptidase and, internalization
activities, is highly expressed in the epithelial cells of the prostate gland and is strongly
upregulated in prostatic adenocarcinoma, with elevated expression correlating with,
metastasis, progression, and androgen independence. Recently, PSMA has been an
active target of investigation by several approaches, including the successful utilization
of small molecule inhibitors, RNA aptamer conjugates, PSMA-based immunotherapy,
and PSMA-targeted prodrug therapy. Future investigations of PSMA in prostate cancer
(PCa) should focus in particular on its intracellular activities and functions. The objective
of this contribution is to review the current role of PSMA as a marker for PCa diagnosis,
imaging, and therapy.
Keywords: prostate cancer, prostate-specific membrane antigen, PSMA, small molecule inhibitors, RNA aptamer
conjugates, PSMA-based immunotherapy, PSMA-targeted prodrug therapy, positron emission tomography
INTRODUCTION
Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane glycoprotein with folate
hydrolase and carboxypeptidase, and internalization activities. This internalization capability is
increased up to 3-fold when PSMA is linked to anti-PSMA antibodies. PSMA expression is highest
in prostate tissue (secretory acinar epithelium), but detectable levels of PSMAprotein are also found
in the kidney (proximal tubules), the small bowel (i.e., jejunal brush border), neuroglia (Schwann
cells and astrocytes), and salivary glands (1, 2). Notably, PSMA is highly expressed in prostate
cancer cells and the vessels of various non-prostatic solid tumors (it is not expressed in the normal
vasculature) (3).
With the rise and evolution of several targeted approaches to examine prostate cancer using
PSMA, the aim of this contribution is to review the current role of PSMA as a marker for PCa
diagnosis, imaging, and therapy.
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EXPRESSION AND ROLE OF PSMA IN PCA
PSMA was originally discovered using the monoclonal antibody
7E11 obtained from the cell membrane of the LNCaP cell line
(4). It has been shown by immunohistochemistry that expression
of PSMA at the tissue level increases through the progression
from normal prostate cells to high-grade prostatic intraepithelial
neoplasia (HGPIN) and to PCa (3) (Figure 1). There exists
a strong positive correlation between PSMA expression and
Gleason score. Elevated PSMA expression is strongly correlated
with a high serum PSA. These indications are associated with
increased tumor angiogenesis and lack of ets-related gene
(ERG) expression which leads to reduced vitamin D and
androgen receptor expression (5). PSMA expression is regulated
by the androgen receptor (AR). PSMA expression increases
dramatically during androgen-deprivation therapy (6).
Downregulation of PSMA expression by ARmay be associated
to the presence of an enhancer region although no androgen
response elements have been identified (7).
PSMA expression is significantly correlated with prostate
growth and differentiation (8). In particular, in vitro expression of
PSMA is associated with an increased cellular folate content. This
induces a proliferative property to cells expressing PSMA (9, 10).
In addition, PSMA stimulates PCa cell proliferation, migration
and survival through the phospho-p38 (P-p38) MAPK pathway
in LNCaP cancer cells (11). Guo et al. demonstrated that PSMA
knockdown in a LNCaP cell line was associated with not only the
inhibition of the pathway of phosphatidylinositol 3-kinase/Akt
signaling but also decreased cell proliferation, migration and
survival (12).
PSMA is involved in the development of PCa metastases.
Xu et al. evaluated four prostate cancer cell lines (i.e., DU145,
LNCap, PC-3, and 22RV1) for metastasis-related genes
potentially involved in PCa metastasis regulated by PSMA.
In their study, CDH6, MMP3, and MTSS1 were seen as
PSMA-related genes. Their expression was inversely related
with the stage of cancer, thus suggesting their possible
involvement in the suppression of PCa metastasis by
PSMA (13).
PSMA-BASED IMAGING IN PATIENTS
WITH PCA
Conventional imaging techniques, such as ultrasound, CT, bone
scintigraphy and Magnetic Resonance Imaging (MRI), are at
present utilized to detect primary PCa and its metastatic deposits.
However, the limitation of such traditional imaging techniques
andmodalities is their low sensitivity in the detection of recurrent
or/and metastatic PCa. Improved imaging modalities are needed
to optimize the management of the patients with PCa.
Positron Emission Tomography (PET) and single photon
emission computed tomography (SPECT) with emerging
radiopharmaceuticals provide more accurate staging for primary
cancer, detection of metastatic disease, and restaging of tumor
recurrence. PSMA has received considerable attention as a useful
marker for imaging purposes in patients with PCa (14, 15).
Several PSMA-based approaches have been developed, including
antibodies, nanobodies, and small molecule inhibitors.
Antibodies and Nanobodies
Indium-111 capromab pendetide (111In-capromab,
ProstaScint R©) was the first monoclonal antibody against PSMA
used in PCa immunoscintigraphy. Correlation of scan results
with tissue specimens showed that 111In-capromab detected soft
tissue metastases, with an average negative predictive value of
70%, sensitivity of 60%, and positive predictive value of 60%
(16–18). However, 111In-capromab lacks sensitivity because it
recognizes an intracellular epitope of PSMA, thereby targeting
only apoptotic/necrotic or damaged cells.
Unlike 111In-capromab, J591 is an antibody against the
extracellular domain of PSMA. 111In-labeled J591 has been
evaluated against conventional imaging techniques in the
evaluation of bone metastases. 111In-labeled J591 identifies 93.7%
of skeletal lesions detected by a conventional imaging technique.
Thirteen out of Eighteen bone deposits detected only with 111In-
labeled J591 were successively confirmed to be metastases (19).
In a more recent study, J591 has been radiolabeled with 89Zr (20)
and 64Cu (21) for PET imaging and demonstrate robust targeting
of skeletal, nodal and soft tissue metastasis (22).
A new strategy in the development of high-contrast nuclear
imaging is the utilization of specific antibody fragments,
called nanobodies. Nanobodies contain antibody-derived
smaller fragments (typically the variable domain alone
of heavy chain antibodies) that largely retain the specific
antigen binding properties of the original antibodies, but
with more rapid pharmacokinetics and lower immunogenic
potential. Evazalipour et al. compared the properties of different
nanobodies radiolabeled with 99 m-Technetium (99 mTc) in
PSMA+ LNCaP and PSMA− PC3 cell lines and in PSMA− and
PSMA+ tumor-bearing xenografts through SPECT/micro-CT
imaging and tissue analysis. Among the evaluated molecules,
nanobody PSMA30 resulted in an important compound for
future applications in PCa imaging trials (23).
Interesting results were also obtained with minibodies, i.e.,
IAB2M, an 80-kDa minibody genetically engineered from the
parent antibody J591 that targets the extracellular domain
of PSMA. A phase I dose-escalation study in patients with
metastatic prostate cancer demonstrated PET imaging with 89Zr-
Df-IAB2M is feasible and well tolerated, and targets both bone
and soft-tissue disease (24).
Small Molecules
The identification of the functional (25) and structural
(26) homology between N-acetylaspartylglutamate peptidase or
NAAALDASE (for which a number of enzymatic inhibitors had
been identified) (27, 28) and PSMA has been a major step
forward for the development of PSMA-targeted radiotracers.
Generally, small molecule PSMA inhibitors consist of zinc
binding compounds linked to a glutamate isostere or glutamate.
Phosphonate-, phosphate-, and phosphoramidates (1) and ureas
(2) constitute the two main families of compounds. Based
on NAALADASE homology, several compounds have been
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FIGURE 1 | Brain metastasis of prostate cancer with cribriform pattern (A), showing low expression of PSA (B), and intense expression of PSMA (C).
developed and labeled with 123I (20, 29, 30), 99mTc (21, 31), 18F
(32), 111In (33), and 68Ga (34).
123I-MIP-1072 and 123I-MIP-1095 were the first small
molecule inhibitors of PSMA adopted in the clinic. SPECT/CT
using these compounds showed a rapid detection of PCa deposits
in the bone, soft tissue, and prostate gland of men with metastatic
PCa (35). A phase I trial on 131I-MIP-1095 in men with mCRPC
is now active (NCT03030885).
Among the emerging PSMA small molecule inhibitors, N-
(N-((S)-1,3-dicarboxypropyl) carbamoyl)-4-(18F)fluorobenzyl-
L-cysteine (18F-DCFBC) is under evaluation in several ongoing
studies. Using 18F-DCFBC, PSMA+ PC-3 PIP xenografts were
early visualized with little radioactivity in the PSMA− isogenic
PC-3 flu xenografts. After 2 h, the PC-3 PIP xenografts remained
visible, with clearance of background radioactivity from kidneys,
liver and blood (36, 37).
The use of 18F-DCFBC has been investigated in a few patients
with Gleason scores between 7 and 9 and with radiological
evidence of metastatic PCa. Bone scans or CT identified 21
lesions (5 bone and 16 lymph node lesions), while 32 lesions
were visible with 18F-DCFBC PET. Ten of Eleven additional
lesions were located in the bone and were suggestive of early
bone deposits, indicating the potential of 18F-DCFBC PET in this
subpopulation (38). Currently, the use of 18F-DCFBC PET/CT
is under evaluation in a study enrolling patients scheduled for
surgical prostate (Group 1), or with biochemical recurrence after
surgery or radiotherapy (Group 2), or in metastatic PCa patients
(Group 3) (NCT02190279). In addition, another ongoing phase
I/II study is assessing the potential of 18F-DCFBC PET in the
detection of primary PCa, nodal and bone metastases in men at
initial diagnosis (NCT01496157) (Table 1).
As for the PSMA inhibitor 18F-DCFPyL (2-(3-{1-carboxy-
5-((6-((18)F)fluoro-pyridine-3-carbonyl)-amino)-pentyl}-
ureido)-pentanedioic acid), Chen et al. evaluated its use in
immunocompromised mice utilizing isogenic PSMA PC3 PIP
and PSMA- PC3 flu xenografts, suggesting that this agent could
be viable and effective in this setting (32). A phase I study
is now assessing the biodistribution and pharmacokinetic of
18F-DCFPyL in patients with advanced PCa (NCT02151760).
The early distinction between local disease and metastasis is
crucial in the management of patients with PCa. 18F-choline
can distinguish lesions with moderate to good sensitivity, but
its activity is limited to patients with a PSA >1 ng/mL (39).
The results obtained by 68Ga-labeled PSMA inhibitors showed
a high potential in the detection of small recurrent PCa lesions
in patients with low levels of serum PSA (40–42). Indeed,
68Ga-labeled PSMA inhibitors are characterized by accumulation
in small metastatic deposits and a rapid clearance from the
tissue in the background (43). Recently, a comparison between
PET/CT and PET/MRI hybrid systems using a 68Ga-labeled
PSMA compound for the detection of recurrent PCa has been
performed. The results showed that Ga-PSMA PET/MRI was far
more accurate in the detection of PCa and, at the same time,
associated with lower radiation exposure (34).
Beyond 68Ga-labeled compounds, 99mTc-labeled inhibitors
of PSMA have shown great promise in the detection of
PCa lesions. Presently, a phase II study is testing 99mTc-
MIP-1404 PSMA inhibitor in patients with high-risk PCa
scheduled for radical prostatectomy (RP) surgery including
extended pelvic lymph node (LN) dissection compared to
histopathology (NCT01667536). Results are expected from the
completed phase 3 trial proSPECT-AS (NCT02615067). Primary
outcome measures of the study are sensitivity and specificity
of 99mTc-MIP-1404 SPECT/CT image assessments to correctly
detect clinically significant prostate cancer when compared
to histopathology following either RP or prostate biopsy in
men with newly diagnosed PCa whose biopsy indicates a
histopathologic Gleason Score of ≤ 3+ 4.
Furthermore, BAY1075553 [2-PMPA analogs (2S, 4S)-
2-18F-fluoro-4-(phosphonomethyl) pentanedioid acid] has
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TABLE 1 | Current completed trial on PSMA-based imaging.
NCT Identifier Study phase Tracer and technique Study outcomes
NCT01496157 Phase 1
Phase 2
18F-DCFBC PET PET detection of primary and sextant localization of PCa and detection of
metastatic disease at initial staging
NCT02048150 Phase 1 MDX1201-A488 Assess the best dose given before robotic assisted laparoscopic RP to aid
in visualization of the prostate
NCT02151760 Phase 1 18F-DCFPyL Compare diagnostic accuracy of 18-DCFPyL to CT and bone scintigraphy
for the detection of metastatic PCa
NCT01667536 Phase 2 99mTc-MIP-1404 Assessment of the diagnostic accuracy in detection PCa within the prostate
and metastatic PCa
NCT03558711 Phase 1 18F-PSMA Safety of administration
NCT02611882 Phase 1
Phase 2
Ga-68 HBED-CC
PSMA
SE and SP for the detection of nodal metastasis in high-risk pre-RP
patients, of metastatic disease in patients with BCR after RP or radiation
therapy, comparison to conventional imaging in CRPC patients.
NCT03486886 Not
Applicable
PSMA -PET/CT Evaluation of detection Yield performance and reproducibility in mPCa
Patients
NCT02796807 Phase 2 68Ga-HBED-CC-
PSMA
PET/CT
Correlation Between SUV on 68Ga-HBED-CC-PSMA and GS in PCa
NCT02488070 Phase 1
Phase 2
68Ga-PSMA PET/CT Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal
Biodistribution
NCT01359189 Phase 1 ProxiScan Evaluation of a Transrectal Scintigraphic Detector (ProxiScanTM) for
Detection of Primary PCa
NCT02918357 Phase 2
Phase 3
Ga-68 labeled
PSMA-11 PET
Sensitivity and PPV of for the detection of metastases a per-patient and
per-region-basis confirmed by histopathology
NCT02916537 Phase 1 CTT1057 PET/MR Evaluation of the safety, pharmacokinetics, and [18F] radiation dosimetry
NCT00712829 Phase 1 123-I-MIP-1072
123-I-MIP-1095
Evaluating the safety, pharmacokinetics, tissue distribution
NCT01615406 Phase 1 99mTc MIP 1404 Comparison study of 99mTc-MIP-1404 (SPECT)/CT imaging to histology
NCT01261754 Phase 1 99mTc-MIP-1404 and
MIP-1405
Safety, pharmacokinetics, biodistribution in mPCa patients; newly
diagnosed, high-risk PCa and healthy subjects
NCT01572701 Phase 1 99mTc-MIP-1404 Measure activity counts in tissue samples post-surgery, Intensity of
99mTc-MIP-1404 Uptake with Respect to PSMA expression in Men With
PCa Undergoing RP and/or PLND
NCT02190279 Early phase 1 18F-DCFBC PET/CT Assess the ability to identify sites of localized, recurrent and metastatic PCa
NCT00992745 Phase 1 123-I-MIP-1072 Estimate the imaging SE and SP of 123I MIP 1072 compared to 111In
capromab pendetide in mPCa
NCT02349022 Phase 2 [89Zr]Df-IAB2M Compare SE/SP/PPV/NPV/Accuracy of [111In] capromab pendetide
SPECT/CT to [89Zr]-Df-IAB2M PET/CT as confirmed by pathology
NCT02615067 Phase 3 99mTc-MIP-1404
SPECT/CT
Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect
Clinically Significant PCa in Men With Biopsy Proven Low-Grade PCa
Candidates for AS (proSPECT-AS)
ACTRN12617000005358 Phase 2 Ga-68 PSMA-PET/CT Compare the diagnostic accuracy of Ga-68 PSMA-PET/CT to that of
conventional imaging for detecting nodal or distant metastatic disease.
Source: https://clinicaltrials.gov.
PSMA, Prostate specific membrane antigen; RP, radical prostatectomy; MDX1201-A488, Anti-PSMA monoclonal antibody; PCa, prostate cancer; SE, sensitivity; SP, specificity; BCR,
biochemical recurrence; CRPC, castration resistant prostate cancer; GS, Gleason score; PPV, positive predictive value; 123-I-MIP-1072, MIP 1404, MIP-1405, small molecule inhibitor
of PSMA; PLND, Pelvic Lymph Node Dissection; NPV, negative predictive value; AS, active surveillance.
demonstrated high uptake in PSMA+ LNCaP tumor xenografts
(44). The phase I study showed that BAY1075553 was able to
detect primary PCa, lymph node and bone metastases, although
its high uptake with degenerative bone lesions may limit its use
in assessing bone disease (45).
Worth mentioning is the registrational phase II/III OSPREY
study (NCT02981368) that evaluated the diagnostic accuracy of
18F-DCFPyL PET/CT relative to histopathology, for detecting
PCa in pelvic lymph nodes in patients with high risk localized
prostate cancer who are planned for RP with lymphadenectomy,
and in patients with locally recurrent or metastatic disease willing
to undergo biopsy.
Imaging at Diagnosis of PCa
A number of recent studies has dealt with the use of PSMA-based
imaging for the purpose of diagnosing primary PCa (Figure 2).
Fendler et al. assessed the accuracy of 68Ga-PSMA-11
PET/CT in identifying PCa at the initial diagnosis in men with
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FIGURE 2 | 68Ga-PSMA ligand PET/CT exhibits solitary left iliac
radiotracer-positive lymph node.
biopsy-proven PCa (46). They found that the optimal SUVmax
cutoff for distinction of histopathology-positive segments from
histopathology-negative segments is of 6.5. With this approach
they obtained 67% sensitivity, 92% specificity, 97% positive
predictive value, and 72% accuracy.
Woythal et al. (47) evaluated the association of intraprostatic
68Ga-PSMA PET/CT features and PSMA immunohistochemical
expression in 31 patients who underwent RP and preoperative
68Ga-PSMA-11 PET/ CT. 68Ga-PSMA-11 PET/CT demonstrated
sensitivity and specificity of 87 and 97%, respectively, in the
detection of PCa. However, there was no correlation between
Gleason Score (GS) and the SUVmax of PCa.
On the other hand, Uprimny et al. (48) found that PCa with
a GS of 6, 7a (3 + 4) and 7b (4 + 3) showed lower 68Ga-
PSMA-11 uptake, with SUVmax of 5.9, 8.3, and 8.2, respectively,
compared to men with a GS greater than 7 (median SUVmax:
21.2). In addition, men with a PSA of 10.0 ng/mL or above it
showed a greater uptake than those patients with PSA levels
below 10.0 ng/mL.
The correlation of intraprostatic PSMA uptake with clinical
parameter, such as PSA value, GS and d’Amico risk score, was
analyzed by Koerber et al. in 104 patients with newly diagnosed
PCa (49). Results of this study indicated that men with higher
PSA, higher d’Amico risk score and higher GS had greater
intensity of PSMA uptake on PET/CT.
The comparison between the multiparametric Magnetic
Resonance Imaging (mpMRI) and 68Ga-PSMA-11 PET/CT
findings showed a concordance in the detection of intraprostatic
tumor lesions, with the highest GS of 89.55%. By giving
additional molecular imaging information to the mpMRI
features, this method can be improved to avoid false-negative
results or understaging tumors, in particular the detection of
those with the highest GSs. In addition, PSMA PET/ MRI may
prove useful in finding lower rates of indolent cancer detection
and a great number of intermediate- and high-risk tumors.
Imaging at Staging of PCa
For pre-operatory staging, current guidelines recommend at least
abdomino-pelvic cross-sectional imaging (MRI or CT) and a
bone scan, for intermediate- and high-risk PCa (50) only. In
a prospective study 30 patients with intermediate- and high-
risk PCa underwent preoperative 68Ga-PSMA PET/CT followed
by RP and extended pelvic LN dissection. Using pathology as
reference, 68Ga-PSMA PET/CT showed a sensitivity of 64% for
the evaluation of LN metastasis, with a 95% specificity, 88%,
positive predictive value, and 82% negative predictive value (51).
In a prospective, phase II, single center study, Gorin et al.
analyzed the diagnostic value of PSMA targeted 18F-DCFPyL
PET/TC in the preoperative staging of 25 patients considered
to be at high risk for having metastatic PCa, despite a negative
conventional staging result. With this technique, they obtained a
sensitivity and specificity of 71 and 88%, respectively, per patient
analysis and 66 and 92% per LN packet analysis (52).
The retrospective study conducted by Maurer et al. (53)
involved a 130 men with intermediate and high risk PCa staged
with 68Ga-PSMA-PET/magnetic resonance tomography or
PET/CT. The sensitivity, specificity and accuracy of 68Ga-PSMA-
PET were 65.9, 98.9, and 88.5%, and those of morphological
imaging were 43.9, 85.4, and 72.3%, respectively. Such figures are
higher than those for traditional imaging techniques and other
alternative PET tracers. Hence, the addition of 68Ga-PSMA PET
to traditional approaches has the potential to replace current
standard imaging, enabling more complete and accurate primary
staging.
Imaging at Biochemical Recurrence of PCa
In men with biochemical recurrence (BCR) after RP or
radiotherapy the detection rate of 68Ga-PSMA PET/CT increases
with higher pre-scan PSA value. In the post-RP patients the rate
of 68 Ga-PSMA PET/CT was 11.3, 26.6, 53.3, 79.1, and 95.5% for
serum PSA levels of 0.01 to <0.2 ng/mL, 0.2 to <0.5 ng/mL, 0.5
to <1 ng/mL, 1 to <2 ng/mL, and ≥ 2 ng/mL, respectively. In
the post-radiotherapy patients, the rate was 33.3% for PSA 0.01
to< 0.5 ng/mL, 71.4% for PSA 0.5 to<1 ng/mL, 93.3% for PSA 1
to<2 ng/mL, and 100% for PSA≥ 2 ng/mL (54). Such figures are
in agreement with the meta-analysis data by Perera et al. (55). In
that study, on per-patient analysis, the sensitivity and specificity
of 68Ga-PSMA-11 PET were both 86%. On per-lesion analysis,
the sensitivity and specificity were 80 and 97%. 68Ga-PSMA PET
positivity increased with a shorter PSA doubling time.
Higher rates have been reported by Raucher et al. (56) in a
cohort of men with PSA value between 0.2 and 1 ng/ml after RP.
The rate of detection was 55% in men with “very low” serum PSA
(0.2–0.5 ng/ml) and of 74% in patients with “low” PSA (0.5–1.0
ng<ml). In such investigation the most relevant predictors for
68GaPSMA-ligand PET/CT positivity in multivariable analysis
were concurrent androgen deprivation therapy and serum PSA
value. Identification of the sites of recurrent disease is of great
importance, thus avoiding unnecessary localized treatments in
patients of systemic recurrence and avoid the side effects of
systemic treatments in men with localized recurrence (57, 58).
Table 1 summarizes the completed trials on PSMA and
imaging. For additional trials please visit: https://clinicaltrials.
gov.
18F-fluciclovine (Axumin R©) (18F-FACBC) is an amino-acid
targeting radiotracer and not a PSMA based PET/CT agent (59).
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The sensitivity of 18F-fluciclovine PET for identifying recurrent
disease changes with PSA levels, with reported detection rates in
the post-prostatectomy biochemical failure setting of 72.0% (for
PSA values of less than 1 ng/mL) 83.3% (for PSA 1-2 ng/mL),
and 100% for PSA levels of 2 or more ng/mL (60). In patients
with pathologically enlarged lymph nodes, presence of true-
positive lesions was noted in 29% patients with 18F-fluciclovine
vs. 7% patients with CT (61, 62). A prospective study compared
overall detection rate of 18F-FACBC and 11C-Choline PET/CT
on 28 patients with biochemical relapse after RP. Anti-3-18F-
FACBCPET/CT detected 60% additional tumor lesions including
5 (17.8%) additional patients (63).
PSMA-Targeting Strategies for PCa
Therapy
PSMA has been widely utilized as a target antigen due to its
constitutive or induced internalization property as well as to its
high expression in PCa. Several strategies, including peptides,
monoclonal antibodies and aptamers, have been utilized as
nanoparticles or prodrugs to improve targeting efficiency in PCa
cells. The discovery and development of anticancer aptamersmay
prove to be relevant contribution to PCa molecular imaging.
Aptamers are short DNA, RNA or peptide oligomers
able to assume a specific and stable three-dimensional shape
in vivo (64). Their high affinity and specificity, similar to
antibodies, is achieved by a three-dimensional conformation
complementary to the target surface. At this regard, Lupold
et al. identified two RNA aptamers (A9 and A10) characterized
with high binding affinity to PSMA, leading to the inhibition
of its NAALADase/glutamate carboxypeptidase II activity (65).
Successively, Xu et al. conjugated A10 aptamer on the surface of
micelles, showing high drug uptake in PSMA+ cancer cells both
in vitro and in vivo investigations (66).
PSMA can be used as target for delivery of therapeutic agents
such as in antibody-drug conjugated (ADC) therapy. PSMAADC
is a fully human anti-PSMA monoclonal antibody conjugated to
monomethyl auristatin E through a valine-citrulline linker.
Wang and his group assessed the antitumor activity of PSMA
ADC in PCa cell lines in vitro and in a novel in vivo model
of taxane-refractory human PCa. They observed that in vitro
cytotoxic activity was efficient for PCa cells with increased
PSMA expression (>105 molecules/cell; IC50 0.022 nmol/L). In
addition, PSMA ADC showed high in vivo activity in treating
xenograft tumors that have progressed on previous docetaxel
therapy (67).
Petrylak et al. (68) reported data from a phase II trial
based on PSMA-ADC at 2.5 mg/kg in patients with taxane-
refractory metastatic castration-resistant PCa (CRPCa). Thirty-
Nine Percent of the patients had been treated with both
cabazitaxel and docetaxel, while 58% had received both
enzalutamide and abiraterone. Dosing was started at 2.5
mg/kg and adjusted at 2.3 mg/kg for tolerability. The study
demonstrated that PSA decline of 30% or more was observed
in 36% (2.3 mg/kg) and 16% (2.5 mg/kg). Circulating tumor
cell (CTC) decline of ≥50% was seen in 74% patients in
both 2.3 and 2.5 mg/kg. Duration of therapy on 2.3 mg/kg
was far longer than on 2.5 mg/kg, as well as the rate of
FIGURE 3 | The targeting ligand binds to PSMA on prostate cancer cells. Once bound to the neoplastic cell, 177Lu atom releases an energetic beta and gamma
particles that results in a DNA-damaging radiation.
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serious adverse events (37 vs. 59%). Notably, PSA and CTC
decline was associated with higher PSMA expression + CTC
level, while PSA responses alone were correlated with lower
neuroendocrine (NE) marker expression, thus suggesting that
NE differentiation may have a role in this context. On the
basis of such results, this study has been further extended (see
NCT02020135).
Phage display technology has been used by researchers in the
identification of peptide sequences, which can bind to PSMA
and, at the same time, inhibit its enzymatic activity. Denmeade
et al. conjugated a PSMA-specific peptide to an inhibitor
(i.e., Thapsigargin) of the sarcoplasmic/endoplasmic reticulum
calcium adenosine triphosphate (SERCA) pump. The type of
pump shares the catalytic properties of ion-motive ATPases of
the P-type family. It transports calcium ions from the cytoplasm
into the sarco-endoplasmic reticulum. Its activity is needed for
viability by all types of cells. The conjugate remains inactive
until the PSMA-specific peptide is cleaved, thereby starting
SERCA inhibition. In xenograft models, thapsigargin induced
tumor regression at doses that appeared to be minimally toxic
TABLE 2 | Selection of trials of PSMA-based therapy (Selection based on active and completed trials).
NCT identifier Study phase Drug Study objectives (Number of patients) Study results
NCT01695044
NCT02020135
Phase 2
(Extension Study)
PSMA ADC Assess total serum PSA response, CTC
response, overall radiologic response in
mCRPC pts (119 pts- completed 17 pts) in two
groups: (1) CHT-experienced and (2) CHT
naïve.
-PSA response:
>30% Decrease in PSA:
29% (1); 32% (2).
>50% Decrease in PSA:
11% (1); 21% (2).
-CTC response
>30% Decrease in CTC: 81%
(1), 92% (2).
>50% Decrease in CTC:
74%(1),85%(2). -Overall
radiologic response
Stable disease 61% (1),69% (2);
Progressive disease:
13% (1), 9% (2);
Partial response: 0 (1), 6% (2)
NCT01414283 Phase 1 PSMA ADC Determine the maximum tolerated dose of
PSMA ADC (13 weeks) (52 pts)
No results posted
NCT01414296 Phase 1
Extended
39-Week
PSMA ADC Safety and tolerability of PSMA ADC as
measured by all adverse events in mCRPC
patients (10 pts)
No results posted
NCT00705835 Phase 1 Rs-PSMA Safety, tolerability, and immune response of
vaccine therapy with increasing dose levels of
rsPSMA protein (14 pts)
No results posted
NCT00015977 Phase 2 PSMA peptide
vaccine
Immunization with PSMA peptide vaccine
followed by injection of Interleukin-12 in
Metastatic PCa patients, determinate disease
response (13 pts)
No results posted
NCT01140373 Phase 1 Autologous T cells
targeted to PSMA
Safety and tolerability using increasing doses of
engineered autologous T cells targeted to
PSMA after cyclophosphamide in CMPC
patients (13 pts)
No results posted
NCT02202447 Phase 1 EC1169 Safety, pharmacokinetic profile and preliminary
efficacy of PSMA Targeting-Tubulysin
Conjugate EC1169 in Patients With Recurrent
Metastatic CRPC (40 pts)
No results posted
NCT00694551 Not Applicable Polypeptide
vaccines:
PSMA27-35-
PSMA687-701
Pilot immunotherapy study of combination
PSMA and TARP peptide with Poly IC-LC
adjuvant in patients with elevated PSA after
initial definitive treatment (29 pts)
Adverse events (Grade 3 or
higher): 0 pts
PSA doubling: 19/29 pts; No
PSA doubling: 10/29 pts
NCT00916123 Phase 1 177Lu-J591 Effectiveness of 177Lu-J591 antibody in
combination with docetaxel chemotherapy
against metastatic CRPC (15 pts)
No results posted
For a full list of trials please visit: https://clinicaltrials.gov PSMA ADC, Prostate Specific Membrane Antigen Antibody Drug Conjugate; CHT, chemotherapy; PSA, prostatic specific
antigen; CTC, Circulating tumor cells; 177Lu- J591, Anti-prostate-specific Membrane Antigen Monoclonal Antibody; CMPC, Castrate Metastatic Prostate Cancer; TARP, T-cell receptor
γ alternate reading frame protein; CRPC, castrate-resistant prostate cancer; Rs-PSMA, Recombinant Soluble PSMA.
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(69). Based on such findings, a phase I study is evaluating the
Thapsigargin prodrug G-202 in patients with advanced PCa and
other solid tumors (NCT01056029).
PSMA can be used in immunotherapy and radiotherapy
approaches. “Adoptive immunotherapy based on infusion of
designer T cells engineered with chimeric antigen receptors
(CARs)” to potentiate their antitumor activity could serve
as a highly specific modality for the treatment of cancer.
Thus, PSMA×CD3 diabody is able to retarget human CD4+
and CD8+ lymphocytes to lyse PSMA-expressing C4-2 PCa
cells. Other 1st and 2nd generation anti-PSMA designer T
cells have shown their activity in both in vitro and in vivo
studies (70). More recently, mouse-human chimeric IgG1 of
2C9 (KM2777) has been fused with C-terminus interleukin-
2 (IL-2). In a xenograft tumor model using PSMA-expressing
PCa cells, this fusion, KM2812, showed evident antitumor
activity, with complete regression in some cases (71). Bispecific
antibodies have been utilized in human clinical trials. A
phase I trial has studying the safety of adoptive transfer of
autologous T cells targeted to PSMA for the treatment of
castrate metastatic PCa patients (NCT01140373). Vaccine is
another very important area that utilizes PSMA as a target to
increase cellular and humoral immune responses against tumor
cells (72).
Concerning the potential role of PSMA targeted antivascular
radiotherapy, Bandekar et al. has evaluated liposomes loaded
with the α-particle generator 225Ac to kill in a selective manner
PSMA positive PCa cells. In such study, anti-PSMA–targeted
liposomes have been able to kill PSMA positive cells, including
the endothelial cells expressing PSMA, thus suggesting their use
for selective antivascular radiotherapy (73).
Therapy of Metastatic Castration Resistant
PCa (CRPCa) With Radiopharmaceuticals
Recently, studies have explored the role of PSMA-based
treatments with radiopharmaceuticals of metastatic
castration resistant PCa (Figure 3). The first antibody-based
radiotherapeutic was Yttrium-90 (90Y) capromab. Phase 1 (74)
and Phase 2 (75) studies were unsuccessful for significant toxicity
and lack of efficacy.
J591 was the first humanized monoclonal antibody directed
against the extracellular domain of PSMA (76). The PSMA
antibody–based radiotherapeutic Lutetium-177 J591 (177Lu-
J591) showed acceptable toxicity with evident targeting of
known metastatic sites in a phase 1 trial. In phase II,
almost 60% of men showed a decline in serum PSA levels,
10.6% of them experiencing a >50% decline in PSA (77).
Myelosuppression associated with treatment was reversible.
“Fractioned dosing allowed for higher cumulative doses with
less toxicity” (78). However, there are limitations to the
use of PSMA antibody—based radiotherapeutic. Lutetium-177
J591, i.e., slow diffusion of the antibodies into solid tumor
lesions and hematotoxicity caused by a long circulation time
in the blood (79). Retrospective studies have caveats such
as treatments that have been done outside of clinical trials,
unrecognized and unmeasured covariates that might influence
final results.
A recent systematic review showed that 43% of the men
showed a maximum decline of serum PSA of ≥50% following
treatment with 177Lu-PSMA radioligand therapy (RLT). In
particular, 177Lu-PSMA RLT gave objective remission and
decline of PSA of ≥50%, more often than with third-line
treatments (enzalutamide and cabazitaxel). Median survival was
longer after 177Lu-PSMA RLT than after third-line treatment,
the difference being not significant from statistically point of view
(80).
A promising available option for patients with mCRPC
is the recently investigated compound PSMA–DKFZ-617, a
small molecule peptide, rather than an antibody, chemically
conjugated with 177Lutetium that binds with high affinity to
PSMA. Unlike antibodies such as J591, it shows more rapid
plasma clearance, higher affinity binding to PSMA and lower
toxicity. Interesting outcomes came up from a single-arm,
single-center, phase 2 trial (ACTRN12615000912583) recently
published by Hofman et al. (81, 82). Patients with mCRPC
and progressive disease after standard treatments underwent
screening PSMA and FDG-PET/CT to confirm high PSMA-
expression. After four cycles of intravenous [1
77
Lu]-PSMA-617,
17 (57%) of 30 patients (95% CI 37–75) obtained a PSA
decrease of 50% or more, objective response in nodal or visceral
disease in 14 (82%) of 17 patients with measurable disease and
reported minor toxic effects and improvement in pain severity.
Phase 3 trial of 177Lu-PSMA-617 (NCT03511664) is currently
recruiting. A multicenter randomized trial comparing LuPSMA
with cabazitaxel chemotherapy (NCT03392428) is ongoing.
Table 2 summarizes a selection of active and completed trials
on PSMA and therapy. For a full list of trials please visit: https://
clinicaltrials.gov.
CONCLUSION
PSMA represents an attractive target for the detection and
treatment of patients with PCa. PSMA immunohistochemical
evaluation should be further investigated as a predictive
marker in men with metastatic PCa, to guide clinicians
in the selection of the most appropriate imaging technique
and therapy in individual patients. The choice of emerging
PSMA-targeted tracers and therapeutic agents requires further
investigation in order to identify the most specific compound
for the distinct sites and phases of the disease (83–85).
As our understanding of the role of PSMA in prostate
carcinogenesis advances and molecular techniques become more
refined, PSMA-based strategies will have a crucial role in the
evolving diagnostic and therapeutic landscape of patients with
PCa.
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